Other Targets

You can also try the following methods, and our professionals will serve you Customized Consultation

Cat. No.	Product Name	Field of Application
DC2086	PF-670462 Featured	PF 670462 is a selective casein kinase, CK1ε and CK1δ inhibitor which also shows potency against 42 other kinases.
DC20027	PF 750 Featured	PF 750 is a selective and covalent fatty acid amide hydrolase (FAAH) inhibitor, with IC50s varied from 16.2-595 nM in different pre-incubation times. Covalently modifies the enzyme’s active site serine nucleophile.
DC21500	PF-00610355	PF-00610355 (PF 610355) is a potent, selective, and long-acting β2-adrenoreceptor agonist with EC50 of 0.26 nM.
DC21495	PF-02413873	PF-02413873 (PF-2413873) is a potent, selective, fully competitive, and orally active progesterone receptor (PR) antagonist with Ki of 9.7 nM.
DC23574	PF-02575799	PF-02575799 is a highly potent microsomal triglyceride transfer protein (MTP) inhibitor with IC50 of 0.77 nM.
DC21470	PF-03049423	PF-03049423 is a potent, selective, orally active, and brain penetrant inhibitor of PDE5 with IC50 of 0.2 nM.
DC8382	PF-03084014 (Nirogacestat) Featured	PF-03084014 (PF-3084014) is a selective gamma-secretase inhibitor with IC50 of 6.2 nM in a cell-free assay. Phase 2.
DC21496	PF-03382792	PF-03382792 (PF-3382792) is a clinical compound under phase 1 investigation for an unknown indication..
DC23622	PF-03463275	PF-03463275 (PF 3463275) ia an orally bioavailable, centrally penetrant, potent, reversible, selective, and competitive inhibitor of the human GlyT1 transporter with Ki of 13 nM.
DC23422	PF-03654746	PF-03654746 (PF 3654746) is a potent, selective, orally bioactive antagonist of H3 receptor with Ki of 2.3 nM.
DC23448	PF-03654764	PF-03654764 (PF 3654764) is a potent, selective, orally bioactive antagonist of H3 receptor with Ki of 1.4 nM.
DC21483	PF03715455 Featured	PF-03715455 is a potent inhaled p38 MAPK inhibitor. PF-03715455 shows some selectivity for p38α over p38β with respective IC50 values of 0.88 and 23 nM. PF-03715455 potently inhibits LPS-induced TNFα production in human whole blood (IC50=1.7 nM). PF-03715455 has potential for the treatment of COPD (chronic obstructive pulmonary disease)[1][2].PF-03715455 is a moderate inhibitor of CYP1A2, CYP2C19, and CYP2D6 and a potent inhibitor of CYP’s 2C9 and CYP3A4[2].PF-03715455 treatment shows that the Vss and T1/2 are 0.19 L/kg, 1 hour, respectively[2]. Animal Model: Male CD Sprague Dawley rats (300-450 g)[2] Dosage: 1 mg/kg Administration: I.v. (Pharmacokinetic Analysis) Result: The Vss, and T1/2 were 0.19 L/kg, 1 hour, respectively.
DC9367	PF-03814735	PF-03814735 is a novel, potent, orally bioavailable, reversible small-molecule Aurora kinase inhibitor with IC50 of 0.8, 5, 10 and 22 nM for Aurora A, Aurora B, Flt 1 and FAk, respectively.
DC23708	PF-03882845	PF-03882845 is highly potent, selective, nonsteroidal, orally bioavailable Mineralocorticoid receptor antagonist with IC50 of 4.5 nM.
DC21498	PF-04191834	PF-04191834 (PF-4191834) is a potent, non‐iron chelating, non‐redox, selective and competitive inhibitor of 5-lipoxygenase (5‐LO) with Ki of 10 nM.
DC24071	PF-04217903 methanesulfonate Featured	PF-04217903 is a potent, selective, ATP-competitive c-Met kinase inhibitor with Ki of 4.8 nM, inhibits HGF-stimulated tyrosine phosphorylation of wild type c-Met with IC50 of 7.3 nM in cell-based assays.
DC21479	PF-04308515	PF-04308515 (PF 4308515) is a potent glucocorticoid receptor (GR) agonist with anti-inflammatory activity..
DC12550	PF-04449613	PF-04449613 (PF04449613) is a potent and selective inhibitor of PDE9..
DC26092	PF-04455242 hydrochloride	PF-04455242 is a potent, selective κ-opioid receptor (KOR) antagonist with Ki of 3 nM/21 nM/22 nM for hKOR/rKOR/mKOR, respectively.
DC23423	PF-04455242	PF-04455242 is a potent, selective κ-opioid receptor (KOR) antagonist with Ki of 3 nM/21 nM/22 nM for hKOR/rKOR/mKOR, respectively.
DC9442	PF-04457845 Featured	PF-04457845 is a potent and exquisitely selective inhibitor of FAAH, with an IC50 of 7.2 nM, and both analgesic and antiinflammatory effects in animal studies comparable to naproxen.
DC21499	PF-04531083	PF-04531083 (PF 4531083) is a potent and selective, orally available sodium channel Nav1.8 blocker for treatment of pain. .
DC22408	PF-04634817	PF-04634817 is a potent, orally bioavailble CCR2 and CCR5 chemokine receptor antagonist for the treatment of diabetic nephropathies and diabetic macular oedema. .
DC22409	PF-04634817 succinate	PF-04634817 is a potent, orally bioavailble CCR2 and CCR5 chemokine receptor antagonist, for the treatment of diabetic nephropathies and diabetic macular oedema. .
DC23682	PF-04677490	PF-04677490 is a potent, selective PDE1 inhibitor with IC50 of 21 nM for PDE1B.
DC23631	PF-04701475	PF-04701475 is a nove positive allosteric modulator of AMPA receptor, a prototype used to explore AMPAR-mediated pharmacology in vivo..
DC23600	PF-04856264 Featured	PF-04856264 is a potent, selective Nav1.7 blocker with IC50 of 28 nM, dispalys >1,000-fold selectivity over Nav1.5.
DC22113	PF-04895162	PF-04895162 (ICA-105665, PF 4895162) is an orally available agonist of neuronal Kv7 potassium channel, opens Kv7.2/7.3 and Kv7.3/7.5 potassium channels, also known as KCNQ2/3 and KCNQ3/5 channels.
DC23629	PF-04958242	PF-04958242 is a novel potent, selctive, and orally-active AMPA receptor (AMPAR) positive allosteric modulator (PAM) with Ki of 170 nM, EC50 of 370 nM.
DC20164	PF-04965842 (Abrocitinib) Featured	PF-04965842 is a selective Janus kinase 1 (JAK1) inhibitor, demonstrating potent activity against JAK1 with an IC50 of 29 nM. Its selectivity is evident from its significantly higher IC50 values for other JAK family members: 803 nM for JAK2, > 10,000 nM for JAK3, and 1,250 nM for TYK2. This selectivity profile suggests that PF-04965842 preferentially targets JAK1 over other JAK isoforms, which could be advantageous in reducing off-target effects and improving therapeutic outcomes in conditions where JAK1 signaling is implicated.

Other Targets

Customized Consultation X

Your information is safe with us. * Required Fields.